The current financial score of Dr Reddy's Laboratories Ltd is 7.75. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 853.73M, representing a year-over-year decrease of 14.53%, while its net profit experienced a year-over-year decrease of 71.69%.
The current valuation score of Dr Reddy's Laboratories Ltd is 8.46. Its current P/E ratio is 21.57, which is 22.36% below the recent high of 26.39 and 28.64% above the recent low of 15.39.
The current earnings forecast score of Dr Reddy's Laboratories Ltd is 6.50. The average price target is 13.56, with a high of 15.60 and a low of 11.40.
The current price momentum score of Dr Reddy's Laboratories Ltd is 3.12. Currently, the stock price is trading between the resistance level at 13.02 and the support level at 11.81, making it suitable for range-bound swing trading.
The current institutional shareholding score of Dr Reddy's Laboratories Ltd is 3.00. The latest institutional shareholding proportion is 14.05%, representing a quarter-over-quarter increase of 1.56%. The largest institutional shareholder is James Simons, holding a total of 7.35M shares, representing 0.15% of shares outstanding, with 20.14% decrease in holdings.
The current risk assessment score of Dr Reddy's Laboratories Ltd is 8.44. The company's beta value is 0.27. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.